CBP-1018 is the first dual-ligand conjugate drug targeting PSMA and FRα developed on Coherent Biopharma (CBP)’s Bi-XDC technolo...
March 13th-16th，2023, London｜Invited by the Annual World ADC committee, Dr. Robert HUANG, the Founder and CEO of Coherent Biopharma Group attended the 13th Annual World ADC London and delivering a speech…
The third Bi-Ligand-Drug conjugate CBP-1019 of Coherent Biopharma was granted the FDA's clinical implied licenseon January 18, 202...
The 2022 American Association for Cancer Research (AACR) annual meeting will be held from April 8 to 13, 2022 in New Orleans. Alon...
● The preliminary clinical results showed that CBP-1008 has manageable safety profile. Evident antitumor activity was obser...
